Paper528374
Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy.
Dantchev D and 4 others. J Antibiot (Tokyo), 1979. Cited by 96 papers, by iCite.
Cite this record
ConductScience Library. Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy. Papers, record 528374. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/528374
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Alopecia | Major topic |
| Cardiomyopathies | Major topic |
| Doxorubicin | Major topic |
| Animals | |
| Cricetinae | |
| Mesocricetus | |
| Mice | |
| Myocardium | |
| Skin | |
| Time Factors |
Source PubMed
Cited by28
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 96 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40205399 | Comparison of hyperthermic intravesical chemotherapy using pirarubicin and Bacillus Calmette-Guérin in the treatment of patients with high-risk non-muscle-invasive bladder carcinoma: a retrospective study. | BMC Urol | 2025 | https://conductscience.org/library/papers/40205399 | PubMed |
| 39390209 | Improved survival among elderly patients with aggressive adult T-cell leukemia/lymphoma: Impact of mogamulizumab-containing chemotherapy. | Int J Hematol | 2024 | https://conductscience.org/library/papers/39390209 | PubMed |
| 37238419 | Pirarubicin Combination Low-Dose Chemotherapy for Early Infantile Stage MS Neuroblastoma: Case Report. | Children (Basel) | 2023 | https://conductscience.org/library/papers/37238419 | PubMed |
| 37205905 | Oral vinorelbine and continuous low doses of cyclophosphamide in pediatric rhabdomyosarcoma: a real-world study. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37205905 | PubMed |
| 36575000 | A multicenter, phase II study of full-dose THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, aggressive non-Hodgkin lymphoma. | J Clin Exp Hematop | 2022 | https://conductscience.org/library/papers/36575000 | PubMed |
| 34193755 | A multicenter, phase II study of R-THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, indolent B-cell lymphoma. | J Clin Exp Hematop | 2021 | https://conductscience.org/library/papers/34193755 | PubMed |
| 32907549 | Efficacy of combination-chemotherapy with pirarubicin, ifosfamide, and etoposide for soft tissue sarcoma: a single-institution retrospective analysis. | BMC Cancer | 2020 | https://conductscience.org/library/papers/32907549 | PubMed |
| 31649535 | Dual Inhibition of Pirarubicin-Induced AKT and ERK Activations by Phenformin Sensitively Suppresses Bladder Cancer Growth. | Front Pharmacol | 2019 | https://conductscience.org/library/papers/31649535 | PubMed |
| 28824057 | 3A Comparison between R-THP-COP and R-CHOP Regimens for the Treatment of Diffuse Large B-cell Lymphoma in Old Patients: A Single-institution Analysis. | Intern Med | 2017 | https://conductscience.org/library/papers/28824057 | PubMed |
| 25432694 | Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter? | Med Oncol | 2015 | https://conductscience.org/library/papers/25432694 | PubMed |
| 22580740 | Pirarubicin inhibits multidrug-resistant osteosarcoma cell proliferation through induction of G2/M phase cell cycle arrest. | Acta Pharmacol Sin | 2012 | https://conductscience.org/library/papers/22580740 | PubMed |
| 20033628 | Long-term results of pirarubicin versus doxorubicin in combination chemotherapy for aggressive non-Hodgkin's lymphoma: single center, 15-year experience. | Int J Hematol | 2010 | https://conductscience.org/library/papers/20033628 | PubMed |
| 20016539 | Long-term results of the Japanese Childhood Cancer and Leukemia Study Group studies 811, 841, 874 and 911 on childhood acute lymphoblastic leukemia. | Leukemia | 2010 | https://conductscience.org/library/papers/20016539 | PubMed |
| 7805181 | Treatment of advanced hormone-refractory prostate carcinoma with a combination of etoposide, pirarubicin and cisplatin. | Cancer Chemother Pharmacol | 1995 | https://conductscience.org/library/papers/7805181 | PubMed |
| 6687222 | Activity of 4'-0-tetrahydropyranyladriamycin hydrochloride (THP-ADM) in a human tumor cloning system. | Invest New Drugs | 1983 | https://conductscience.org/library/papers/6687222 | PubMed |
| 6678865 | Phase I clinical trial of a new anthracycline: 4'-o-tetrahydropyranyl adriamycin. | Invest New Drugs | 1983 | https://conductscience.org/library/papers/6678865 | PubMed |
| 4017162 | Pharmacokinetics and disposition of 4'-O-tetrahydropyranyladriamycin in mice by HPLC analysis. | Cancer Chemother Pharmacol | 1985 | https://conductscience.org/library/papers/4017162 | PubMed |
| 3667166 | A phase II study of (2"R)-4'-0-tetrahydropyranyladriamycin (THP) in hematological malignancies. | Invest New Drugs | 1987 | https://conductscience.org/library/papers/3667166 | PubMed |
| 3478154 | (2"-R)-4'-o-tetrahydropyranyladriamycin, a new anthracycline derivative; its effectiveness in lymphoid malignancies. | Cancer Chemother Pharmacol | 1987 | https://conductscience.org/library/papers/3478154 | PubMed |
| 3315282 | Treatment of acute leukemia and malignant lymphoma with (2"R)-4'-O-tetrahydropyranyladriamycin. | Cancer Chemother Pharmacol | 1987 | https://conductscience.org/library/papers/3315282 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/528374
GET https://conductscience.org/api/papers/v1/528374/cited_by?page=2